Studies have shown a higher risk of cardiovascular disease in patients treated with aromatase inhibitors (AI) compared to tamoxifen, though this elevation in risk may be explained by a cardioprotective effect of tamoxifen [12, 13]. Here, CYP19A1 is linked to cardiovascular disorder.